Arrowhead Pharmaceuticals, Inc. (ARWR)
Chart Events
Performance Outlook
| Previous Close | 82.20 |
| Open | 83.01 |
| Bid | 79.66 x 800 |
| Ask | 80.45 x 1200 |
| Day's Range | 79.00 - 84.34 |
| 52 Week Range | 19.51 - 92.60 |
| Volume | 1,061,886 |
| Avg. Volume | 891,696 |
| Market Cap | 8.268B |
| Beta (5Y Monthly) | 1.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.00 |
| Earnings Date | May 05, 2021 - May 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 92.42 |
Fair Value
Related Research
- Insider Monkey
Is Arrowhead Pharmaceuticals (ARWR) Stock a Buy For 2021?
Baron Health Care Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here. During the fourth quarter of 2020, the Baron Health Care Fund returned 17.1% (institutional shares). In comparison, the benchmark S&P 500 Index was up 12.15%, while the Russell 3000 Health Care Index was up 10.08%. You should […]
- Simply Wall St.
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Popular Amongst Institutions?
A look at the shareholders of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership.
- Zacks Small Cap Research
ARWR: Multiple Data Readouts in 2021…
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Multiple Catalysts in 2021 Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is developing medicines that cause gene silencing using RNA interference (RNAi), a specific means of inhibiting the expression of genes and stopping the production of a specific protein. The company has a deep and diverse pipeline consisting of
